³ÉÈË¿ìÊÖ

This issue is being considered by the Scottish Government in conjunction with NHS Boards.

The Charter of Patient Rights and Responsibilities was published in September 2012 and reviewed in September 2017. As a result and in response to views expressed by participants, Ministers agreed that further revision of the Charter of Patient Rights and Responsibilities is necessary. This work is currently underway and involves engagement with key stakeholders and service users.

I refer the member to the answer to question S5W-21701 on 4 March 2019. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at

The Scottish Government recognises the important role of primary care teams in delivering care to patients living with advanced, serious illness or at the end of lives, and their loved ones.

The Daffodil Standards for GPs provides a useful resource for practice teams who wish to improve on the care that they provide to people near the end of life. We will consider if there is more we can do to ensure all GP practices are aware of the standards and this resource.

Prescribing data is not associated with diagnostic data in the Prescribing Information System (PIS) dataset or in the Hospital Medicine Use Database (HMUD). It is reasonable to make the assumption that the prescription of these drugs indicates the patients are being treated for advanced Parkinson’s disease.

The number of people prescribed apomorphine and duodopa in Primary Care in the 12 months up to November 2018 is shown in Table 1.

Table 1. Number of people prescribed apomorphine and duodopa in the community in Scotland in the 12 months up to November 2018.

The information requested is not held centrally. However, the number of hospital discharges where a diagnosis of Parkinson’s disease was recorded, per year, for the last 10 years in Scotland, is available.

Note that the same person may be counted more than once in these figures, and that they do not include patients with Parkinson’s disease who were not admitted to hospital during this period.

Number of discharges from an acute hospital with a diagnosis of Parkinson’s disease recorded, by year, Scotland, 2009-18*.

SIGN is part of the Evidence Directorate of Healthcare Improvement Scotland and receives core funding from Healthcare Improvement Scotland. It is editorially independent from Healthcare Improvement Scotland and the Scottish Government.

Any group or individual can propose or request a review of a SIGN guideline by completing a proposal form and returning it to the SIGN Executive. Guideline topics are selected on the basis of burden of disease, the existence of variation in practice, and the potential to improve outcomes. There is a defined process that SIGN follows to support proposers to develop their proposals and then selection criteria that aid the Guideline Programme Advisory Group to decide which proposals to accept for guideline development. The SIGN Council ratifies these accepted proposals.

Since 1999 over 67,000 cancer patients have accessed clinical trials in Scotland, broken down by NHS Board as shown in the following tables:

I refer the member to the answer to question S5W-21607 on 27 February 2019. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at

This information is not held centrally. The member may wish to consider contacting individual Health Boards to obtain this information.